Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Australia

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) announced the issuance of a new patent from the Australian Patent Office for its drug SLS-005, aimed at treating neurodegenerative diseases linked to protein aggregation. The patent covers a method of intravenous administration of trehalose to address conditions such as oculopharyngeal muscular dystrophy and spinocerebellar ataxia. Trehalose helps stabilize proteins and activates autophagy, potentially reducing the impact of misfolded proteins in cells, as demonstrated in animal studies.

Positive

• Issuance of the patent strengthens Seelos' intellectual property portfolio.
• SLS-005 targets multiple neurodegenerative diseases, indicating a broad market potential.
• Trehalose shows promise in reducing protein aggregation, supported by animal study data.

Negative

• None.

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been granted a patent from the Australian Patent Office (Australian patent number 2019204513) covering SLS-005 titled: "Treatment of Protein Aggregation Myopathic and Neurodegenerative Diseases by Parenteral Administration of Trehalose".

The issued patent covers a method for treating a disease associated with abnormal protein aggregation and/or inclusion body formation in myocytes, neurons, extracellular compartments, or alleviating at least one symptom associated therewith, in a human subject in need thereof comprised of an intravenous administration of a therapeutically effective amount of a pharmaceutical formulation, with trehalose as the sole active ingredient, that complies with other parameters regarding the formulation characteristics and duration of intravenous administration, as described in the patent application.

The issued patent covers a method of using trehalose (SLS-005) to treat several neurodegenerative conditions including oculopharyngeal muscular dystrophy (OPMD), spinocerebellar ataxia (SCA) associated with a polyglutamine repeat mutation, Friedreich's ataxia, spinal and bulbar muscular atrophy (SBMA), dentatombral-pailidoluyssan atrophy (DRPLA), Pick's disease, corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia, and parkinsonism linked to chromosome 17 (FTDP-17).

About Trehalose
Trehalose is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier, stabilizes proteins, and importantly activates autophagy which is the process that clears material from cells. In several animal models of diseases, associated with abnormal cellular protein aggregation or storage of pathologic material, it has been shown to reduce aggregation of misfolded proteins and reduce accumulation of pathologic material. Trehalose activates autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression. Activation of TFEB is an emerging therapeutic target for a number of diseases with pathologic accumulation of storage material.

Contact Information
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-issuance-of-a-patent-for-trehalose-sls-005-in-australia-301217769.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What is the recent patent issued to Seelos Therapeutics related to?

The recent patent pertains to SLS-005, covering the treatment of neurodegenerative diseases by intravenous administration of trehalose.

What diseases does SLS-005 aim to treat?

SLS-005 aims to treat conditions such as oculopharyngeal muscular dystrophy, spinocerebellar ataxia, and other related neurodegenerative diseases.

When was the patent for SLS-005 issued?

The patent for SLS-005 was issued on January 29, 2021.

What is trehalose and why is it significant for Seelos Therapeutics?

Trehalose is a disaccharide that stabilizes proteins and activates autophagy, making it significant for treating diseases linked to protein aggregation.

How does the new patent impact Seelos Therapeutics' market position?

The patent enhances Seelos Therapeutics' intellectual property, potentially solidifying its market position in developing treatments for neurodegenerative diseases.